Corvus Pharmaceuticals Inc
Follow $CRVS
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $CRVS by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is CRVS moving today?
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
CRVS overview
Related filings and maps
Congress activity in CRVS
No receipt-qualified Congressional disclosure is present for CRVS in the cached public ledger.
CRVS contract awards, year to date.
Public federal awards linked to this ticker.
CRVS lobbying filings, year to date.
Registered lobbying filings matched to Corvus Pharmaceuticals Inc.